ASX healthcare share undervalued post earnings

Morning Star AU

17 hours ago

Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to $1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2662798264"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662798264\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662798264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662798264","market":"hk","top_or_hot":-1,"title":"ASX healthcare share undervalued post earnings","media":"Morning Star AU","content":"<div>\n<p>Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to $1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been ...</p>\n\n<a href=\"https://www.morningstar.com.au/stocks/asx-healthcare-share-undervalued-post-earnings\">Source Link</a>\n\n</div>\n","source":"morningstar_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASX healthcare share undervalued post earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASX healthcare share undervalued post earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-26 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.morningstar.com.au/stocks/asx-healthcare-share-undervalued-post-earnings><strong>Morning Star AU</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to $1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been ...</p>\n\n<a href=\"https://www.morningstar.com.au/stocks/asx-healthcare-share-undervalued-post-earnings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NOBL","symbol_name":"ProShares S&P 500 Aristocrats ETF","start_time":0,"source_url":"https://www.morningstar.com.au/stocks/asx-healthcare-share-undervalued-post-earnings","article_id":"2662798264","we_media_id":null,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-healthcare-share-undervalued-post-earnings","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662798264","pubTimestamp":1787673600,"columns":[],"sourceInfo":{"source_id":"morningstar_stock","name":"Morning Star"},"weMediaInfo":null,"summary":"Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to $1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been ","collect":0,"end_time":0,"defaultTopTitle":"morningstar.com.au","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NOBL":"ProShares S&P 500 Aristocrats ETF","VGFPF":"Vanguard Funds PLC","VHT":"Vanguard Health Care ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","RGLO":"Global Equity Active ETF","GXDW":"Global X Dorsey Wright Thematic ETF","TCAF":"T. Rowe Price Capital Appreciation Equity ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","VOTE":"TCW Transform 500 ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","IXJ":"全球医疗业ETF-iShares","CGCV":"Capital Group Conservative Equity ETF"},"translate_title":"ASX healthcare 股票盈利后被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":1.5,"VGFPF":1.5,"CGCV":1.5,"IXJ":1.5,"TCAF":1.5,"PMDE":1.5,"RGLO":1.5,"VOTE":1.5,"GXDW":1.5,"NOBL":1.5,"FEBU":1.5,"VHT":1.5,"JOYT":1.5},"content_text":"Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to $1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been set at $1.95 billion-$2.03 billion at constant currency. Shares fell almost 10% on Aug. 20.Why it matters: While the result met our estimates, Sonic’s pathology unit faces headwinds in fiscal 2027. Regulatory changes in Switzerland are likely to cut EBITDA by $35 million on lower fees for some tests. Protracted integration of the already margin-dilutive HWE contract in the UK will weigh.Indiscernible organic growth in the underperforming US unit remains a drag. It is little wonder the midpoint of the constant-currency EBITDA guidance range equates to growth of just $57 million, or 3%, even after including close to $30 million in restructuring benefits in the US.All this is before the impact of adverse currency movements. If current spot rates hold, they could detract up to $50 million from fiscal 2027 EBITDA, wiping out much of the gain implied at the midpoint of the constant-currency guidance.The bottom line: These headwinds force us to downgrade our fiscal 2027 underlying EBITDA by 6% to $1.945 billion. But the cuts are more moderate beyond and not enough to change our $27 fair value estimate for narrow-moat Sonic. Shares are trading 20% below our intrinsic assessment.The negative response to the tepid near-term outlook has seen the shares give away much of the month-long rally heading into the result. However, we maintain our constructive longer-term view premised on EBITDA margin recovery to 19.2% midcycle, from 17.8% in fiscal 2026.Organic revenue growth is running at mid-single-digit levels, even with the US struggling. Integration of LADR is on track, with 40% of projected synergies achieved in the first year. Optimization initiatives are bearing fruit with more to come. And the balance sheet is in solid shape.Sonic Healthcare reports in-line fiscal 2026, but near-term outlook cloudySonic Healthcare provides laboratory medicine/pathology and diagnostic imaging radiology. It is the third-largest private provider of laboratory medicine globally, behind Quest Diagnostics and Labcorp. Strategy focuses on being a low-cost provider and gaining cost advantage over competitors through scale. This has mostly been pursued through acquisitions, buying smaller operators to expand its market share in geographies where it operates. The firm emphasizes medical leadership, recognizing referring doctors as the primary customer, focusing on improving their experience and efficiency.Sonic has grown via acquisitions in multiple regions, first in its home market Australia, where it’s the largest operator with over 40% of the pathology market and 10% of the diagnostic imaging market. Pathology operates under a hub-and-spoke model, whereby multiple collection facilities feeding centralized laboratories, acquisition synergies procurement, and IT integrations mean most acquisitions are accretive.The same roll-up strategy is used internationally, and Sonic is now the largest private pathology provider in Germany, the UK, and Switzerland, and a major provider in Belgium, New Zealand, and the US. In most international markets, pathology providers face similar pressures, with government reimbursements lagging testing costs. We see consolidation in Europe and the US as likely, as smaller operators are eventually outcompeted by larger providers with lower costs per test.Sonic is navigating lower testing volumes since the end of the covid-19 pandemic, and higher labor costs fueled in part by postpandemic inflation. Profits peaked at AUD 1.5 billion in fiscal 2022 and more than halved to AUD 0.5 billion in fiscal 2024, similar to fiscal 2018 levels. This, alongside concerns about potential German healthcare and reimbursement reform leading to cuts to payments for pathology tests, has weighed on the shares.We forecast group profitability improving, driven by rationalization of its US anatomical pathology operations, increasing testing volumes in the UK from its new Watford laboratory, and cost savings from the integration of the acquisition of LADR in Germany.Bulls sayThe business is defensive, providing an essential service, not tied to economic cycles.Sonic has large market shares in most geographies it operates, including being the largest pathology provider in Australia and Europe.Growth is leveraged to long-term tailwinds from an aging population and increasing levels of testing per person.Bears sayEarnings are tied to government policy and funding, and changes in policy to government rebates for laboratory medicine and imaging.Growth has been in part fueled by acquisitions; improvements in profitability are tied to unlocking synergies and scale benefits from mergers.Returns on invested capital are only modestly above WACC, suggesting the value of any moat is modest.Subscribe to get Morningstar insights in your inbox","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}